Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 4/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | FADS1 | O60427 | 2/20 | 0.37 |
| ▸ | F2 | P00734 | 3/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5763275 | 1.00 | F10 (0.41) | F10MAOAFADS1F2DGAT1 | |
| SCHEMBL5766169 | 1.00 | F10 (0.41) | F10MAOAFADS1F2DGAT1 | |
| SCHEMBL6040388 | 0.90 | MAOA (0.49) | F10MAOAFADS1DGAT1 | |
| SCHEMBL3044472 | 0.90 | MAOA (0.49) | F10MAOAFADS1DGAT1 | |
| SCHEMBL3043386 | 0.90 | MAOA (0.49) | F10MAOAFADS1DGAT1 | |
| SCHEMBL3043385 | 0.90 | MAOA (0.49) | F10MAOAFADS1DGAT1 | |
| SCHEMBL6040387 | 0.90 | MAOA (0.49) | F10MAOAFADS1DGAT1 | |
| SCHEMBL5762074 | 0.82 | F10 (0.45) | F10MAOAFADS1F2DGAT1 | |
| SCHEMBL6040255 | 0.82 | F10 (0.45) | F10MAOAFADS1F2DGAT1 | |
| SCHEMBL5765894 | 0.82 | MAOA (0.62) | F10MAOAFADS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7141588-B2 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PFIZER, INC. (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1478629-B1 | N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATIVES AND THEIR USE AS ANTIBACTERIALS | PHARMACIA & UPJOHN CO LLC (US) | 2006-10-11 | — | — | EP | disclosed |
| US-7049443-B2 | Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound | PHARMACIA & UPJOHN COMPANY (US) | 2006-05-23 | — | — | US | disclosed |
| US-6919329-B2 | N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY (US) | 2005-07-19 | — | — | US | disclosed |
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-29 | — | — | US | disclosed |
| US-20040044052-A1 | N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY | 2004-03-04 | — | — | US | disclosed |
| US-20040014967-A1 | Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound | PHARMACIA & UPJOHN COMPANY | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | F10 4479/4885MAOA 957/4885FADS1 2487/4885 |
| US-20040044052-A1 | N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | F10 4479/4885MAOA 957/4885FADS1 2487/4885 |
| US-20040014967-A1 | Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound | AADAC, AAAS, SLC7A1 | F10 2380/4885MAOA 1179/4885FADS1 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.